Avenue Therapeutics Inc (OTC: ATXI) is a clinical-stage pharmaceutical company that develops drug product candidates requiring FDA approval before any commercial sale. The company generates no product revenue and funds operations through equity issuances, warrant exercises, and external financing. As of the 10-K filed March 30, 2026, Avenue carries accumulated deficits and has been delisted from Nasdaq, with its common stock trading on the OTC Markets system effective March 19, 2025, following a Nasdaq Hearings Panel determination that the company violated Listing Rule 5550(b)(1) by failing to maintain minimum stockholders' equity of $2,500,000. The company expects to continue incurring significant operating losses for the foreseeable future and cannot guarantee that additional funding will be available on acceptable terms. No product revenues have been reported, and profitability is not anticipated in the near term.

Revenue model

No product revenue as of the 10-K filed March 30, 2026. Operations are funded through equity issuances, including common stock sold under an at-the-market agreement and warrant inducement offerings, as well as stock issuances to related parties such as Fortress.

Products and services

Drug product candidates in clinical development requiring FDA approval. No products have received marketing approval as of the filing date. The company references potential future commercial infrastructure needs including sales and marketing personnel and third-party warehousing and distribution, but no commercial products are disclosed in the excerpts.

Customers and end markets

No commercial customers as of the 10-K filed March 30, 2026. Target end markets, if products receive approval, would involve patients and healthcare providers in indications addressed by the company's product candidates. Specific indications are not named in the provided excerpts.

Value-chain role

Clinical-stage drug developer positioned upstream of commercialization. Contracts with third parties for hazardous material disposal and would rely on third parties for warehousing, distribution, and cash collection if products reach commercial stage.

Geographic exposure

Operates in the United States and references FDA as primary regulatory authority, with mentions of regulatory authorities outside the United States in the context of clinical trials.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Dermata Therapeutics Inc Evoke Pharma Inc Grapefruit USA, Inc Johnson & Johnson Stablecoin Development Corp Sonoma Pharmaceuticals Inc Senestech Inc Stem Holdings, Inc.